Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth

European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24

Aarti Drugs posts Q1 FY25 PAT lower at Rs. 33.3 Cr

Rusan Pharma’s API plant in Ankleshwar receives USFDA GMP approval

Rusan’s API facility in Ankleshwar is GMP approved by other stringent international agencies as well

Briefs: Family Care Hospitals, Laurus Labs and Bafna Pharmaceuticals

Laurus Labs receives EIR from USFDA for API facilities

Briefs: Dr. Reddy's Laboratories and Ami Organics

Dr. Reddy's Laboratories gets Form 483 from USFDA with 4 observations for API facility

Supriya Lifescience FY24 PAT up 32%

The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23

Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site

Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history

Briefs: Lupin and Aurobindo Pharma

Lupin updates on shipment of Mirabegron ER Tablets

USFDA completes inspection of Lupin's Dabhasa facility with no observations

The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations

Spriya Lifescience Q3 FY24 PAT jumps 213% at Rs. 29.79 Cr

EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore